Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citation
Cited by
Items 701–800 of 1,004
Shane, E. J., Cohen, A., Stein, E. M., McMahon, D. J., Zhang, C. A., Young, P., Pandit, K., Staron, R. B., Verna, E. C., Brown, R., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2804 · Cited by 45
The Case for Routine Parathyroid Hormone Monitoring
Sprague, S. M., & Moe, S. M. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04650512 · Cited by 41
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
Lewiecki, E. M. (2011) · Drug, Healthcare and Patient Safety · doi:10.2147/dhps.s7727 · Cited by 41
“…risk of atrial fibrillation as a serious adverse event has been reported in a single randomized, placebo-controlled trial of zoledronic acid, 74 another potent antiresorptive agent, suggesting the possibility that this might be a class effect of bisphosphonates Notes: These are listed as…”
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis
Josse, R. G., Khan, A. A., Ngui, D., & Marla Shapiro, C. M. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.763779 · Cited by 43
Cardiovascular Effects of Calcium Supplements
Reid, I. R. (2013) · Nutrients · doi:10.3390/nu5072522 · Cited by 42
“While zoledronate has not been studied with and without calcium in the context of a head-to-head trial, the effects of zoledronate without calcium supplementation appear to be very comparable to those found when a supplement is coadministered [ 35, 36 ] .”
BackgroundSelf-citationGlendenning, P., Chubb, S. A. P., & Vasikaran, S. D. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.03.009 · Cited by 49
Hayes, K. N., Winter, E. M., Cadarette, S. M., & Burden, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051140 · Cited by 48
“Landmark trial extensions and current observational evidence that provide the bulk of evidence on drug holidays of two to three years’ duration have been conducted exclusively in women [7,15,42,43].”
BackgroundColeman, R. E., Burkinshaw, R., Winter, M. C., Neville-Webbe, H. L., Lester, J., Woodward, E., & Brown, J. E. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.540387 · Cited by 46
“[14] Prevention of skeletal-related events in metastatic bone disease from breast cancer: Rosen et al.”
BackgroundChotiyarnwong, P., McCloskey, E. V., Harvey, N. C., Lorentzon, M., Prieto‐Alhambra, D., Abrahamsen, B., Adachi, J. D., Borgström, F., Bruyère, O., CAREY, J. J., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01117-6 · Cited by 48
Could Strontium Ranelate Have a Synergistic Role in the Treatment of Osteoporosis?
Blake, G. M., Compston, J. E., & Fogelman, I. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090601 · Cited by 38
Use of bisphosphonates for the treatment of stress fractures in athletes
Shima, Y., Engebretsen, L., Iwasa, J., Kitaoka, K., & Tomita, K. (2008) · Knee Surgery Sports Traumatology Arthroscopy · doi:10.1007/s00167-008-0673-0 · Cited by 41
A Comprehensive Approach to Fragility Fractures
Rebolledo, B. J., Unnanuntana, A., & Lane, J. M. (2011) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e3181f9b389 · Cited by 44
Effects of ageing, prolonged estrogen deficiency and zoledronate on bone tissue mineral distribution
Brennan, M. Á., Gleeson, J. P., O’Brien, F. J., & McNamara, L. M. (2013) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2013.08.029 · Cited by 41
Ip, T., Cheung, S.-K. W., Cheung, T.-C., Choi, T.-C., Chow, S.-L. E., Ho, Y.-Y. A., Kan, S.-Y. A., Kung, W. C. A., Lee, K.-K., Leung, K. L. F., et al. (2013) · PubMed · Cited by 51
Calcitonin: A useful old friend.
Srinivasan, A., Wong, F. Y. K., & Karponis, D. (2020) · PubMed Central · Cited by 61
The effect of treatments for osteoporosis on mortality
Grey, A. B., & Bolland, M. J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2176-6 · Cited by 40
Bone fractures after menopause
The ESHRE Capri Workshop Group (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq008 · Cited by 56
Bisphosphonates and risk of atrial fibrillation: a meta-analysis
Kim, S. C., Kim, M. J., Cadarette, S. M., & Solomon, D. H. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2938 · Cited by 39
“Another meta-analysis by Mak and colleagues [21] showed no evidence of an increased risk of AF related to bisphosphonate use in their meta-analysis of four randomized clinical trials [5,6,36,37] and three non-experimental studies (one cohort and two case-control studies) [7,14,19].”
BackgroundScott, D. F., Woltz, J. N., & Smith, R. R. (2012) · The Journal of Arthroplasty · doi:10.1016/j.arth.2012.08.007 · Cited by 40
Therapy for patients with CKD and low bone mineral density
Ott, S. M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.182 · Cited by 42
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials
Mocellin, S., Pilati, P., Briarava, M., & Nitti, D. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv318 · Cited by 42
Peng, J. P., Liu, Y., Chen, L., Peng, K., Zhao, X., Zhang, D., & Xiang, Z. (2016) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.322.9435 · Cited by 42
Driessen, J. H. M., van den Bergh, J. P., van Onzenoort, H. A. W., Henry, R. M. A., Leufkens, H. G. M., & de Vries, F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12843 · Cited by 40
Mortality After Osteoporotic Fractures: What Proportion Is Caused by Fracture and Is Preventable?
Schousboe, J. T. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3216 · Cited by 44
“used a meta-analysis of 10 pivotal randomized controlled trials of oral bisphosphonates, strontium ranelate,((72,73)) iv zoledronic acid,((63,74)) and denosumab((75)) to estimate the relative risk of all-cause mortality on pharmacologic fracture prevention medication to be 0.”
MethodIncidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population
Lin, T., Yang, C.-Y., Yang, Y. H. K., & Lin, S. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2624-6 · Cited by 40
Lin, T.-C., Yang, C.-Y., Yang, Y.-H. K., & Lin, S.-J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.62 · Cited by 42
Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies
Reid, I. R. (2011) · Skeletal Radiology · doi:10.1007/s00256-011-1164-9 · Cited by 41
Self-citationHadji, P., Coleman, R. E., Gnant, M., & Green, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds169 · Cited by 40
“In the clinical setting, ZOL has been shown to improve bone mineral density (BMD) in men and women with cystic fibrosis [51], women with postmenopausal osteoporosis [52, 53], and premenopausal women receiving adjuvant chemotherapy for BC [54–56].”
Moshi, M. R., Nicolopoulos, K., Stringer, D., Ma, N., Jenal, M., & Vreugdenburg, T. D. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01078-z · Cited by 44
Yamazaki, T., Yamori, M., Yamamoto, K., Saito, K., Asai, K., Sumi, E., Goto, K., Takahashi, K., Nakayama, T., & Bessho, K. (2012) · Bone · doi:10.1016/j.bone.2012.08.115 · Cited by 40
“025%) [35].”
Fragility fractures in chronic kidney disease: An opinion-based approach
Miller, P. D. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76a.08108 · Cited by 38
Role of biochemical markers in the management of osteoporosis
Henriksen, K., Christiansen, C., & Karsdal, M. A. (2015) · Climacteric · doi:10.3109/13697137.2015.1101256 · Cited by 40
Effect of Teriparatide on Bone Formation in the Human Femoral Neck
Cosman, F., Dempster, D. W., Nieves, J. W., Zhou, H., Zion, M., Roimisher, C., Houle, Y., Lindsay, R., & Bostrom, M. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3698 · Cited by 41
Self-citationDiacinti, D., Vitali, C., Gussoni, G., Pisani, D., SINIGAGLIA, L., Bianchi, G., Nuti, R., Gennari, L., Pederzoli, S., Grazzini, M., et al. (2017) · Bone · doi:10.1016/j.bone.2017.05.008 · Cited by 40
Lateral Femoral Bowing and the Location of Atypical Femoral Fractures
Yoo, H.-S., Cho, Y.-H., Park, Y.-B., & Ha, S.-S. (2017) · Hip & Pelvis · doi:10.5371/hp.2017.29.2.127 · Cited by 40
Tratamiento de la osteoporosis
Nogués, X., & Martínez-Laguna, D. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.10.019 · Cited by 49
Aro, E., Moritz, N., Mattila, K. T., & Aro, H. T. (2018) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2018.04.041 · Cited by 40
Chandran, M., Lau, T. C., Gagnon-Arpin, I., Dobrescu, A., Li, W., Leung, M. Y. M., Patil, N., & Zhao, Z. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0664-4 · Cited by 39
Lyu, H., Zhao, S. S., Yoshida, K., Tedeschi, S. K., Xu, C. Q., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz321 · Cited by 40
Black, D. M., Reid, I. R., Napoli, N., Ewing, S. K., Shiraki, M., Nakamura, T., Takeuchi, Y., Schafer, A. L., Kim, T. Y., & Cauley, J. A. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4434 · Cited by 39
“(8,9) A large 3-year international, randomized, double-blind, placebo-controlled phase 3 study, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT) randomized 7765 women with postmenopausal osteoporosis to either 5 mg ZOL or placebo.”
BackgroundMethodSelf-citationBone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis
Lyritis, G. P., Γεωργούλας, Θ., & Zafeiris, C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05666.x · Cited by 42
Miller, P. D., & Derman, R. J. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1208-3 · Cited by 41
“In postmenopausal women with osteoporosis, bisphosphonates also reduce the risk of nonvertebral fractures [risk reductions relative to placebo are 29% for alendronate, 39% for risedronate, 30% for ibandronate (post hoc analysis), and 25% for zoledronic acid] [39–41] and hip fractures [risk reductions relative to place…”
BackgroundKayan, K., Johansson, H., Odén, A., Vasireddy, S., Pande, K. C., Orgee, J., Kanis, J. A., & McCloskey, E. V. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0942-x · Cited by 41
“vertebral sites, including studies of bisphosphonates, strontium ranelate and teriparatide [25–28].”
BackgroundNarongroeknawin, P., Patkar, N. M., Shakoory, B., Jain, A., Curtis, J. R., Delzell, E., Lander, P., Lopez‐Ben, R., Pitt, M. J., Safford, M. M., et al. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.09.001 · Cited by 39
Causes, consequences, and treatment of osteoporosis in men
Banu, J. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s46101 · Cited by 46
Moore, A. E. B., Blake, G. M., & Fogelman, I. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048595 · Cited by 38
“parathyroid hormone (1-84) on vertebral fracture and bone mineral density in”
BackgroundSclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis
Lewiecki, E. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.540565 · Cited by 39
“Pharmacological therapy proven to reduce fracture risk includes the antiresorptive agents estrogen with or without medroxyprogesterone [16,17], alendronate [18-20], risedronate [21-23], ibandronate [24], zoledronate [25,26], denosumab [27], salmon calcitonin [28], raloxifene [29], bazedoxifene [30] and lasofoxifene [3…”
BackgroundMolecular interactions between zoledronic acid and bone: An in vitro Raman microspectroscopic study
Juillard, A., Falgayrac, G., Cortet, B., Vieillard, M.-H., Azaroual, N., Hornez, J., & Penel, G. (2010) · Bone · doi:10.1016/j.bone.2010.07.018 · Cited by 38
“Zoledronic acid is one of the most powerful BPs, and its efficiency in treating both benign and malignant bone diseases has been well documented [4,5].”
BackgroundBisphosphonates and atypical subtrochanteric fractures of the femur
Kharwadkar, N., Mayne, B., Lawrence, J. E. G., & Khanduja, V. (2017) · Bone and Joint Research · doi:10.1302/2046-3758.63.bjr-2016-0125.r1 · Cited by 42
Huang, T.-W., Wang, C., Shih, H., Chang, Y., Huang, K., Peng, K., & Lee, M. S.-S. (2017) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-017-1577-2 · Cited by 40
Grey, A. B., Horne, A. M., Gamble, G. D., Mihov, B., Reid, I. R., & Bolland, M. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa062 · Cited by 38
Self-citationKondo, H., Okimoto, N., Yoshioka, T., Akahoshi, S., Fuse, Y., Ogawa, T., Okazaki, Y., Katae, Y., Tsukamoto, M., Yamanaka, Y., et al. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01126-w · Cited by 41
Benefits of Bisphosphonate Therapy: Beyond the Skeleton
Billington, E. O., & Reid, I. R. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00612-4 · Cited by 41
Self-citationRisk factors for subsequent vertebral fracture after acute osteoporotic vertebral fractures
Inose, H., Kato, T., Ichimura, S., Nakamura, H., Hoshino, M., Togawa, D., Hirano, T., Tokuhashi, Y., Ohba, T., Haro, H., et al. (2021) · European Spine Journal · doi:10.1007/s00586-021-06741-3 · Cited by 40
“Zoledronic acid reduced the risk of all clinical fractures by 12 months [24].”
BackgroundOvercoming Barriers to Osteoporosis Care in Vulnerable Elderly Patients With Hip Fractures
Switzer, J. A., Jaglal, S. B., & Bogoch, E. R. (2009) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e31815e92d2 · Cited by 38
“Possible OP treatment in this group of patients might include a quarterly or annual intravenous infusion of aminobisphosphonate, which has been shown to increase bone mineral density and reduce the risk of future fracture by 25% to 77%.(4,59) Another treatment option is 50,000 to 100,000 IU vitamin D (which has a long…”
BackgroundCardiovascular Effects of Noncardiovascular Drugs
Raj, S. R., Stein, C. M., Saavedra, P. J., & Roden, D. M. (2009) · Circulation · doi:10.1161/circulationaha.107.728576 · Cited by 40
How to prevent glucocorticoid-induced osteoporosis
Dore, R. K. (2010) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77a.10003 · Cited by 41
Tai, T., Su, F., Chen, C., Jou, I., & Lin, C. (2014) · Bone · doi:10.1016/j.bone.2014.07.003 · Cited by 38
“Therefore, new intravenous drugs such as zoledronic acid (ZA) have been developed that allow dosing at much longer intervals, improving adherence [4].”
BackgroundImaging of Site Specific Bone Turnover in Osteoporosis Using Positron Emission Tomography
Blake, G. M., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0231-2 · Cited by 37
Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials
Lewiecki, E. M., Cooper, C. C., Thompson, E., Hartl, F., Mehta, D., & Papapoulos, S. E. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02335.x · Cited by 37
Schnitzer, T. J., Kim, K., Marks, J., Yeasted, R., Simonian, N., & Chen, D. (2016) · PM&R · doi:10.1016/j.pmrj.2016.01.012 · Cited by 38
“The spine is normally loaded and not denervated after SCI, and this BMD response observed at the spine is in the range of that reported after zoledronic acid treatment of osteoporotic men and women [30,31].”
BackgroundNew horizons in osteoporosis therapies
Harsløf, T., & Langdahl, B. L. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.012 · Cited by 39
Osteoporosis in Postmenopausal Women: Considerations in Prevention and Treatment
Sanders, S., & Geraci, S. A. (2013) · Southern Medical Journal · doi:10.1097/smj.0b013e3182a0df8b · Cited by 42
Kim, T. Y., Bauer, D. C., McNabb, B., Schafer, A. L., Cosman, F., Black, D. M., & Eastell, R. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3654 · Cited by 37
“infusion of zoledronic acid 5mg or placebo and followed for 3 years.((11)) In the E1 extension trial, women who received 3 zoledronic acid or placebo infusions in the core study were eligible to enroll.”
Self-citationPractical guidance for the use of bisphosphonates in osteoporosis
Compston, J. E. (2020) · Bone · doi:10.1016/j.bone.2020.115330 · Cited by 42
Parkinson’s disease and osteoporosis: basic and clinical implications
Figueroa, C. A., & Rosen, C. J. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1756772 · Cited by 44
“Fractures are reduced by 70% in the spine and ~40% in the hip along with improvement of ~6% of BMD in total hip, lumbar spine, and femoral neck [90].”
BackgroundBisphosphonate nephropathy: A case series and review of the literature
van Zuijdewijn, C. L. M. D. R., van Dorp, W., Florquin, S., Roelofs, J. J. T. H., & Verburgh, K. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14780 · Cited by 40
“found more transient increases in serum creatinine in patients treated with zoledronate.(35) The latter finding was confirmed in a randomized, placebo-controlled trial in 5035 postmenopausal osteoporotic women.”
Impact of hormone therapy for women aged 35 to 65 years, from contraception to hormone replacement
KASE, N. G. (2009) · Gender Medicine · doi:10.1016/j.genm.2009.02.001 · Cited by 41
Lespessailles, É., Jaffré, C., Beaupied, H., Nanyan, P., Dolleans, E., Benhamou, C. L., & Courteix, D. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9269-z · Cited by 41
“against fractures in postmenopausal women [3].”
Additive effect of PTH (1–34) and zoledronate in the prevention of disuse osteopenia in rats
Vegger, J. B., Nielsen, E. S., Brüel, A., & Thomsen, J. S. (2014) · Bone · doi:10.1016/j.bone.2014.06.020 · Cited by 39
“Therefore, Zln needs only to be injected once annually in patients, while still efficiently inhibiting osteoclastic activity and thereby reducing the risk of fracture [18].”
BackgroundSafety of drugs used in the treatment of osteoporosis
McGreevy, C., & Williams, D. J. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611411012 · Cited by 38
“In a more recent study, zoledronic acid decreased the risk of vertebral fracture by 70% over a 3-year timeframe versus the placebo group [Black et al. 2007].”
BackgroundDiagnosis and Management of Osteoporosis: A Comprehensive Review of Guidelines
Rentzeperi, E., Pegiou, S., Tsakiridis, I. G., Kalogiannidis, I. A., Kourtis, A., Mamopoulos, A. M., Athanasiadis, A. P., & Dagklis, T. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001181 · Cited by 44
Zoledronic Acid Acutely Increases Sclerostin Serum Levels in Women With Postmenopausal Osteoporosis
Catalano, A., Morabito, N., Basile, G., Brancatelli, S., Cucinotta, D., & Lasco, A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4039 · Cited by 40
“At a dose of 5 mg to treat postmenopausal osteoporosis, zoledronic acid decreases the surrogate markers of bone remodeling, leading to an improvement in bone density and a reduction in fracture risk (9).”
BackgroundClinical role of bisphosphonate therapy
Fogelman, I., & Hampson (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s24783 · Cited by 45
2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2011.05.007 · Cited by 45
Drug-induced atrial fibrillation
Tamargo, J. L., Caballero, R., & Delpón, E. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.698609 · Cited by 38
Fracture Liaison Services: Multidisciplinary Approaches to Secondary Fracture Prevention
Osuna, P. M., Ruppe, M. D., & Tabatabai, L. S. (2016) · Endocrine Practice · doi:10.4158/ep161433.ra · Cited by 38
Principles of Deformity Correction
Orina, J. N., & Berven, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-59713-3_36 · Cited by 36
Ge, X., Yang, L., Jiang, Y. Z., Yang, W., Fu, J., & Li, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101207 · Cited by 38
“Bisphosphonates are currently the most important class of inhibitors of osteoclast mediated bone resorption [9,10] and are used extensively for the treatment of skeletal diseases such as Paget’s disease, [10,11] postmenopausal osteoporosis [10,12] and tumor-induced osteolysis [10,13].”
BackgroundCauley, J. A., Black, D. M., Boonen, S., Cummings, S. R., Mesenbrink, P. G., Palermo, L., Man, Z., Hadji, P., Reid, I. R., & on behalf of the HORIZON Pivotal Fracture Group (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.292 · Cited by 36
“Zoledronic acid was found to significantly reduce vertebral, hip, and all clinical fractures by 70%, 41%, and 33%, respectively.((13)) We present the findings of a prespecified subanalysis of the HORIZON trial to determine the effects of zoledronic acid on the number of days of back pain and the number of days of disa…”
BackgroundMethodInfluentialSelf-citationCardemil, C., Omar, O., Norlindh, B., Wexell, C. L., & Thomsen, P. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.11.003 · Cited by 39
Post-fracture management of patients with hip fracture: a perspective
Bruyère, O., Brandi, M. L., Burlet, N., Harvey, N. C., Lyritis, G. P., Minne, H. W., Boonen, S., Reginster, J.-Y., Rizzoli, R., & Åkesson, K. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802381430 · Cited by 44
Self-citationPotential role of odanacatib in the treatment of osteoporosis
Ng, K. W. (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s26729 · Cited by 42
Edwards, W. B., Schnitzer, T. J., & Troy, K. L. (2013) · Bone · doi:10.1016/j.bone.2013.12.012 · Cited by 37
“The clinical consequence of this bone loss is an increased rate of low-energy fracture [4–8] that is similar to the rate of fracture in post-menopausal osteoporotic women [9,10].”
BackgroundBisphosphonate Therapy and Atypical Fractures
Saleh, A., Hegde, V. V., Potty, A. G. R., & Lane, J. M. (2013) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2013.01.001 · Cited by 40
Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial
Wustrack, R. L., Seeman, E., Bucci-Rechtweg, C. M., Burch, S., Palermo, L., & Black, D. M. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1664-4 · Cited by 35
Self-citationKijowski, R., Tuite, M. J., Krüger, D., del Río, A. M., Kleerekoper, M., & Binkley, N. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1595 · Cited by 39
Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat
Ringe, J. D., & Doherty, J. G. (2009) · Rheumatology International · doi:10.1007/s00296-009-1311-y · Cited by 36
“1%) and NNT (91) values were found for hip fracture over 3 years for risedronate and zoledronate in the Hip Intervention Program (HIP) [25] and HORIZON [23] studies, respectively (Table 2).”
BackgroundInfluentialKomm, B. S., & Chines, A. A. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11422602 · Cited by 39
Clodronate: new directions of use
Frediani, B., & Bertoldi, I. (2015) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2015.12.2.097 · Cited by 41
Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study
Hibler, E. A., Kauderer, J. T., Greene, M. H., Rodriguez, G. C., & Alberts, D. S. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000692 · Cited by 37
“The rationale for this study was based upon the knowledge that bisphosphonates are effective inhibitors of osteoclastic bone resorption,(20,21) the recognition that compliance with long-term oral therapy is poor,(22,23) and data from other studies of zoledronic acid that showed efficacy against risk of facture in othe…”
BackgroundHypercalcaemia and hypocalcaemia: finding the balance
Body, J., Niepel, D., & Tonini, G. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-016-3543-1 · Cited by 38
“quick detection and resolution of hypocalcaemia [79, 91].”
BackgroundKeshishian, A. V., Boytsov, N. N., Burge, R. T., Krohn, K., Lombard, L., Zhang, X., Xie, L., & Baser, O. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4072-6 · Cited by 37
Grossmann, M., Ramchand, S. K., Milat, F., Vincent, A. J., Lim, E., Kotowicz, M. A., Hicks, J., & Teede, H. J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13735 · Cited by 36
Asian ethnicity is associated with atypical femur fractures in an Australian population study
Nguyen, H. H., Lakhani, A., Shore‐Lorenti, C., Zebaze, R., Vincent, A. J., Milat, F., & Ebeling, P. R. (2020) · Bone · doi:10.1016/j.bone.2020.115319 · Cited by 38
Rajapakse, C. S., Johncola, A., Batzdorf, A. S., Jones, B. C., Mukaddam, M. A., Sexton, K., Justine Shults, A., Leonard, M. B., Snyder, P. J., & Wehrli, F. W. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4229 · Cited by 39
“Additional risks, while rare, include atrial fibrillation.((4)) New osteoanabolic agents such as abaloparatide or romosozumab are approved for use for only 24 and 12 months, respectively, highlighting the need for safe and effective agents that could be used long term.”
BackgroundUpdated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective
Raef, H., Al-Bugami, M., Balhareth, S. S., Moawad, M. A., El-Shaker, M., Hussain, A. N., Al-Shaikh, A., & Al-Badawi, I. A. (2011) · Annals of Saudi Medicine · doi:10.4103/0256-4947.77502 · Cited by 38
Calcium Citrate and Vitamin D in the Treatment of Osteoporosis
Gómez, J. M., Blanch‐Rubió, J., Díaz Curiel, M., & Díez‐Pérez, A. (2011) · Clinical Drug Investigation · doi:10.1007/bf03256927 · Cited by 39
Sebba, A. I., Emkey, R. D., Kohles, J. D., & Sambrook, P. N. (2008) · Bone · doi:10.1016/j.bone.2008.10.052 · Cited by 35
“[22] also demonstrated a 30% reduction in the risk of nonvertebral fractures compared with placebo, which is consistent with the expected range of risk reduction with other BPs [24,25].”
ResultOsteoporosis in Men: Epidemiology, Pathophysiology, and Clinical Characterization
ORWOLL, E. S., & KLEIN, R. F. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50044-6 · Cited by 36
Metadata
- Authors
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., & Cummings, S. R.
- Affiliations
- University of California, San Francisco (US)
- Lyon 1 Université (FR)
- University of Sheffield (GB)
- University of Auckland (NZ)
- KU Leuven (BE)
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-03
- Volume
- 356
- Issue
- 18
- Pages
- 1809-1822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993035292
- Cited by
- 2,986
- References
- 34
- Citations by year
- 2026: 90 · 2025: 120 · 2024: 107 · 2023: 96 · 2022: 114 · 2021: 140 · 2020: 127 · 2019: 124 · 2018: 127 · 2017: 121 · 2016: 150 · 2015: 154 · 2014: 154 · 2013: 194 · 2012: 174
- FWCI
- 258.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, vertebral fractures, hip fracture, bone mineral density, bone turnover markers, atrial fibrillation, renal function
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Atrial Fibrillation, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Risk, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.